NO20063757L - Substituerte N-cykloheksylimidazolrnoner med en MCH-modulatorisk virkning - Google Patents

Substituerte N-cykloheksylimidazolrnoner med en MCH-modulatorisk virkning

Info

Publication number
NO20063757L
NO20063757L NO20063757A NO20063757A NO20063757L NO 20063757 L NO20063757 L NO 20063757L NO 20063757 A NO20063757 A NO 20063757A NO 20063757 A NO20063757 A NO 20063757A NO 20063757 L NO20063757 L NO 20063757L
Authority
NO
Norway
Prior art keywords
substituted
cyclohexylimidazolones
compounds
modulatory effect
preparation
Prior art date
Application number
NO20063757A
Other languages
English (en)
Norwegian (no)
Inventor
Matthias Gossel
Lothar Schwink
Siegfried Stengelin
Thomas Boehme
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of NO20063757L publication Critical patent/NO20063757L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D453/00Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70One oxygen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20063757A 2004-01-25 2006-08-22 Substituerte N-cykloheksylimidazolrnoner med en MCH-modulatorisk virkning NO20063757L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004003811A DE102004003811A1 (de) 2004-01-25 2004-01-25 Substituierte N-Cyclohexylimidazolinone, Verfahren ihrer Herstellung und ihre Verwendung als Arzneimittel
PCT/EP2005/000700 WO2005070898A1 (de) 2004-01-25 2005-01-25 Substituierte n-cyclohexylimidazolinone mit mch-modulatorischer wirkung

Publications (1)

Publication Number Publication Date
NO20063757L true NO20063757L (no) 2006-10-11

Family

ID=34745115

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063757A NO20063757L (no) 2004-01-25 2006-08-22 Substituerte N-cykloheksylimidazolrnoner med en MCH-modulatorisk virkning

Country Status (26)

Country Link
EP (1) EP1711473B1 (zh)
JP (1) JP2007518771A (zh)
KR (1) KR20060128955A (zh)
CN (1) CN1934090B (zh)
AR (1) AR047453A1 (zh)
AT (1) ATE383342T1 (zh)
AU (1) AU2005206308A1 (zh)
BR (1) BRPI0507104A (zh)
CA (1) CA2554233A1 (zh)
CY (1) CY1107429T1 (zh)
DE (2) DE102004003811A1 (zh)
DK (1) DK1711473T3 (zh)
ES (1) ES2297667T3 (zh)
HR (1) HRP20080077T3 (zh)
IL (1) IL176917A0 (zh)
MA (1) MA28345A1 (zh)
MY (1) MY139107A (zh)
NO (1) NO20063757L (zh)
PE (1) PE20051091A1 (zh)
PL (1) PL1711473T3 (zh)
PT (1) PT1711473E (zh)
RS (1) RS50543B (zh)
RU (1) RU2006130626A (zh)
TW (1) TW200604182A (zh)
UY (1) UY28726A1 (zh)
WO (1) WO2005070898A1 (zh)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2008129679A (ru) 2005-12-21 2010-01-27 Янссен Фармацевтика Н.В. (Be) Новые замещенные пиразиноновые производные для применения при мсн-1-опосредованных заболеваниях
CA2666193A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use
CA2664112C (en) 2006-12-05 2015-02-17 Janssen Pharmaceutica N.V. Novel substituted diaza-spiro-pyridinone derivatives for use in mch-1 mediated diseases
KR100893394B1 (ko) * 2007-05-11 2009-04-17 한국화학연구원 아릴 피페리딘기-함유 이미다졸 유도체, 이의 제조방법 및이를 유효성분으로 포함하는 약학적 조성물
AR072707A1 (es) 2008-07-09 2010-09-15 Sanofi Aventis Compuestos heterociclicos, procesos para su preparacion, medicamentos que comprenden estos compuestos y el uso de los mismos
DE102008060967A1 (de) * 2008-12-06 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Substituierte Phenylsulfonyltriazolone und ihre Verwendung
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
DK2470552T3 (en) 2009-08-26 2014-02-17 Sanofi Sa NOVEL, CRYSTALLINE, heteroaromatic FLUORGLYCOSIDHYDRATER, MEDICINES COVERING THESE COMPOUNDS AND THEIR USE
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8895547B2 (en) 2011-03-08 2014-11-25 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120058A1 (de) 2011-03-08 2012-09-13 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120050A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120051A1 (de) 2011-03-08 2012-09-13 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
PL223830B1 (pl) 2012-04-03 2016-11-30 Univ Jagielloński Pochodne aromatycznych imidazolidynonów i ich zastosowanie

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200302719A (en) * 2001-12-04 2003-08-16 Schering Corp MCH antagonists for the treatment of obesity
DE10233817A1 (de) * 2002-07-25 2004-02-12 Aventis Pharma Deutschland Gmbh Substituierte Diarylheterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel

Also Published As

Publication number Publication date
RS50543B (sr) 2010-05-07
EP1711473B1 (de) 2008-01-09
DK1711473T3 (da) 2008-05-26
AR047453A1 (es) 2006-01-18
PE20051091A1 (es) 2006-01-23
TW200604182A (en) 2006-02-01
MY139107A (en) 2009-08-28
IL176917A0 (en) 2006-12-10
JP2007518771A (ja) 2007-07-12
CA2554233A1 (en) 2005-08-04
MA28345A1 (fr) 2006-12-01
KR20060128955A (ko) 2006-12-14
HRP20080077T3 (en) 2008-03-31
BRPI0507104A (pt) 2007-06-19
WO2005070898A1 (de) 2005-08-04
CN1934090B (zh) 2010-04-07
DE102004003811A1 (de) 2005-08-11
EP1711473A1 (de) 2006-10-18
PT1711473E (pt) 2008-03-07
ATE383342T1 (de) 2008-01-15
CN1934090A (zh) 2007-03-21
RU2006130626A (ru) 2008-02-27
PL1711473T3 (pl) 2008-05-30
UY28726A1 (es) 2005-08-31
AU2005206308A1 (en) 2005-08-04
CY1107429T1 (el) 2012-12-19
ES2297667T3 (es) 2008-05-01
DE502005002497D1 (de) 2008-02-21

Similar Documents

Publication Publication Date Title
NO20063757L (no) Substituerte N-cykloheksylimidazolrnoner med en MCH-modulatorisk virkning
NO20070176L (no) Nye fluorglykosidderivater av pyrazoler, medikamenter inneholdende disse forbindelsene og anvendelse derav
NO20064201L (no) Glukopyranosylsubstituerte benzolderivater, medikamenter inneholdende slike forbindelser, deres anvendelse og fremstilling
NO20072389L (no) Substituerte benzokinolizinderivater
NO20060908L (no) Substituerte tazol-benzoisotiazoldioksidderivater, deres fremstilling og anvendelse
NO20084307L (no) Heterocykliske GPCR agonister
NO20085066L (no) 4,5-difenyl-pyrimidinyl-aminosubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
NO20074391L (no) CIS-2,4,5-triaryl-imidazoliner og deres anvendelse som anti-cancer medikamenter
NO20080010L (no) GPCR-agonister
NO20082643L (no) Isokinolinaminopyrazolderivater, deres fremstilling og anvendelse som farmasoytiske midler for behandling av kreft
NO20055887L (no) Pyrido'2, 1-A-isokinoliderivater som DPP-IV-inhibitorer
NO20063925L (no) Indazolderivater som inhibitorer av hormonsensitiv lipase
NO20091683L (no) Kjemiske forbindelser
NO20091244L (no) Adenosinderivater som A2A reseptoragonister
MA32272B1 (fr) Inhibiteurs de raf de pyrazole [3,4-b]pyridine
NO20075669L (no) Middel for a behandle ufrivillig bevegelse
CR9078A (es) Derivado de bencimidazol ariloxi-sustituidos
NO20085068L (no) Fenylamino-benzoksazolsubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
NO20065260L (no) Tri(cyklo)substituerte amidforbindelser
BR112014015720A8 (pt) derivados de tieno[3,2-d]pirimidina que têm atividade inibidora de proteinas quinases
NO20082445L (no) Neuropeptid-2 reseptor-agonister
WO2011028947A3 (en) Heterocyclic compounds for the inhibition of pask
ATE523509T1 (de) 13,13a-dihydroberberinderivate, ihre pharmazeutischen zusammensetzungen und verwendung
NO20065926L (no) Substituerte oksazolbenzoisotiazoldioksidderivater samt fremgangsmate for fremstilling og anvendelse derav
BR112013014184A2 (pt) compostos de triazina [1,2,4] triazolo [4,3-b][1,2,4], método de preparo e seu uso

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application